A phase I/II, open-label, prospective, multicenter study to evaluate the efficacy and safety of lower doses of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: The KMM103 study

被引：0

作者：

Min, Chang Ki ^{[1
]}

Park, Sung-Soo ^{[2
]}

机构：

[1] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[2] Catholic Univ Korea, Seoul St Marys Hematol Hosp, Coll Med, Seoul, South Korea

来源：

关键词：

autologous stem cell transplant; bortezomib; myeloma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-033

引用

页码：E216 / E216

页数：1